Literature DB >> 15743333

CSF iron, ferritin and transferrin levels in restless legs syndrome.

Soichi Mizuno1, Takumi Mihara, Tsuyoshi Miyaoka, Takuzi Inagaki, Jun Horiguchi.   

Abstract

The aim of this study is evaluating iron, ferritin, and transferrin in both serum and CSF in patients of restless legs syndrome (RLS), based on the hypothesis that iron deficiency in the central nervous system (CNS) causes the symptoms as a result of the dysfunction of dopaminergic systems. These parameters, polysomnographic sleep measures, and subjective evaluation of the sleep quality were compared in 10 patients of idiopathic RLS (RLS group) and 10 age-matched patients of psychophysiological insomnia without RLS symptoms (non-RLS group). With sleep patterns, sleep latency was longer and sleep efficiency was lower in the RLS group than those in the non-RLS group. Periodic leg movement index in the RLS group was higher than that of the non-RLS group. With serum examination, there were no significant differences for the iron, ferritin, and transferrin values between the both groups. With CSF examination, the iron and ferritin values were lower and the transferrin values were higher in the RLS group than those in the non-RLS group. There was positive correlation between the serum and CSF ferritin levels in the both groups, but the slope of the regression lines for the RLS group was lower than that for the non-RLS group. These results indicate low brain iron concentration caused by the dysfunction of iron transportation from serum to CNS in patients with idiopathic RLS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743333     DOI: 10.1111/j.1365-2869.2004.00403.x

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  80 in total

1.  Restless legs syndrome: relationship between prevalence and latitude.

Authors:  Brian B Koo
Journal:  Sleep Breath       Date:  2011-12-31       Impact factor: 2.816

2.  Iron deficiency anemia in infancy exerts long-term effects on the tibialis anterior motor activity during sleep in childhood.

Authors:  Patricio Peirano; Cecilia Algarin; Rodrigo Chamorro; Mauro Manconi; Betsy Lozoff; Raffaele Ferri
Journal:  Sleep Med       Date:  2012-07-04       Impact factor: 3.492

3.  A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome.

Authors:  Christopher J Earley; Alena Horská; Mona A Mohamed; Peter B Barker; John L Beard; Richard P Allen
Journal:  Sleep Med       Date:  2008-02-14       Impact factor: 3.492

4.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

5.  A 68-year-old woman with sleep-onset insomnia.

Authors:  Norman Wolkove; Marc Baltzan
Journal:  CMAJ       Date:  2013-09-23       Impact factor: 8.262

Review 6.  Pathophysiology of restless legs syndrome: evidence for iron involvement.

Authors:  James R Connor
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

7.  Integrating sleep management into clinical practice.

Authors:  Catherine C Schuman; Hrayr P Attarian
Journal:  J Clin Psychol Med Settings       Date:  2012-03

8.  Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome.

Authors:  Shangru Lyu; Mark P DeAndrade; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li
Journal:  Behav Brain Res       Date:  2019-07-31       Impact factor: 3.332

Review 9.  Animal models of sleep disorders.

Authors:  Linda A Toth; Pavan Bhargava
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

10.  Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome.

Authors:  Richard P Allen; Christopher J Earley; Byron C Jones; Erica L Unger
Journal:  Sleep Med       Date:  2020-02-05       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.